-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LQs7QprOpEs9DWbOFbyZe44PGc8eq08qi2tTA0FiHF/ez9z1Y+mxPdLDuhtcuEhb q4JWujIKQMkOdiNgixpH3Q== 0000000000-08-005409.txt : 20080310 0000000000-08-005409.hdr.sgml : 20080310 20080131080030 ACCESSION NUMBER: 0000000000-08-005409 CONFORMED SUBMISSION TYPE: UPLOAD PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080131 FILED FOR: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: UPLOAD BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 LETTER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C0-)>+CS],-"C8@,"!O8FH-/#PO3&EN96%R:7IE9"`Q+TP@,3`W M,S8O3R`X+T4@-C4T."].(#$O5"`Q,#4W,"]((%L@-3DV(#$V.%T^/@UE;F1O M8FH-("`@("`@("`@("`@("`@("`@("`@#0IX'1=+T5X=$=3=&%T93P\+T=3 M,2`Q.2`P(%(^/CX^#65N9&]B:@TQ,"`P(&]B:@T\/"]3=6)T>7!E+U1R=654 M>7!E+T9O;G1$97-C7!E+T9O;G0^/@UE;F1O8FH- M,3(@,"!O8FH-6R])0T-"87-E9"`Q-2`P(%)=#65N9&]B:@TQ,R`P(&]B:@T\ M/"],96YG=&@@-S@S+T9I;'1EY@13*^0-X2"&WI)+W@MM-A^N`:$=0:F\HF&?Z^NY(-)C!Y M*YZQ);$Z>_;LY>KM7,!CU;M->E=)XH.`9-43/G!\\#/B$``FOPDLL&#<8%D;SV>C$223Q@@/!!/A\2!Y MY>&!XN#*U(X[62*W?`A@Y,59$6F4IS^&A/[%NYF('`R0BH$6SAW*KR/M6J M@$]N[*Q=-$LUR1PY:29WMVM"_R&O`V/R0=\.) MV``#$BRFB"X&,SB6)*'YIW7G3$N]`<&]#[`J-=1KB<)6"`$_9*KAKEC*)4QD M)C>_4-$FS5$W\J`%%,$)X.<#X%\LD5KJ?`];NB>P96)L("3D=:5KBD)J52Y! M&L=SN:T;S]QXCHUG3X0$<8CK*.H"5?7\:4@,]E`P0V/.CV(^M'-TV)H#@ M8O.>*N4;8A,2A$K6UNFUO8)#Q8R"F*#X*9L6MAT7GC$ZGQ#D8W"0T<;Q7<(Z MQ1K+RLTVES6*4>XT:/FDY#.4*]C3EK3&,A:.C4T,V<`/+8L+_;;`$O9<+V(C MYX.9+5KF*2&O5*Z*QXK.W)#0C.>BA-5.8P*;3O(:^-=$6CC(=R.+&L%J3+ZJ MH*:!YD@L78==FF$=Z0,#Z[/8%/^BG5YS%S,JF(^][<=!C-U;N";'&>V'C-"; MA38+LP]I&N3MC;V]T;: MQ89YE_3^"3``YS:L90H-"F5N9'-TJ'-,-(9>I,N,(#T+B`=!%$89@88R@###$ULB*A`1!$1`460 MH(`!HZ%(K(AB(2BH8`]($%!B,(JHJ&1&UDI\>7GOY>7WQ[W?VF?O<_?9>Y^U M+@`D3Q\N+P66`B"9)^`'>CC35X5'T+']``9X@`&F`#!9Z:F^0>[!0"0O-Q=Z MNL@)_(O>#`%(_+YEZ.E/IX/_3]*L5+X``,A?Q.9L3CI+Q/DB3LH4I(KM,R*F MQB2*&4:)F2]*4,1R8HY;Y*6??1;94!&;B)C$#PYT$?%R`'"D MN"\XY@L6<+($XD.YI*1F\[EQ\0*Z+DN/;FIMS:![[M(KT*^-PSB-;W MA^VO_%+J`&#,BFJSZP];S'X`.K8"('?_#YOF(0`D17UKO_'%>6CB>8D7"%)M MC(TS,S.-N!R6D;B@O^M_.OP-??$](_%VOY>'[LJ)90J3!'1QW5@I22E"/CT] ME?^IB?\P M[$]:G&N1*/6?`#7*"$C=H`+DYSZ`HA`!$GE0W/7?^^:##P7BFQ>F.K$X]Y\% M_?NN<(GXD,X`9P\QBL5AYK`'6#NN'96(% MV`+L?NPQ[#GL('8<^Q9'Q*GBS'#NN`@<#Y>'*\$AX1202U8G6Q``B ME[B)6$$\3KQ"'"6^(\F0]$DNI$B2D+23=(1TGG2/](I,)FN3'DDN58R1[)<\J3D#LHERC@50]6A>E$3J$74;ZC]U!E9&=EELJ&R6;)5LF=D M1V@(39OF14NBE=!.T(9H[YGR;O*)\KOE.^0?*:`4]!4"%#(5#BI<4IA6I"K:*K(4"Q5/*-Y7@I7TE0*5 MUBD=5NI3FE564?903E7>KWQ1>5J%IN*HDJ!2IG)694J5HFJORE4M4SVG^HPN M2W>B)]$KZ#WT&34E-4\UH5JM6K_:O+J.>HAZGGJK^B,-@@9#(U:C3*-;8T93 M5=-7,U>S6?.^%EZ+H16OM4^K5VM.6T<[3'N;=H?VI(ZYM/8P>0R]1[X#>37U8WT(_7K]*_X8!;&!IP#4X8#"P%+W4>BEO:=W2 M84.2H9-AAF&SX:@1SJ/U:>MW-I8V`IL3-K_8&MHFVC;9 M3B[76/MC]D/^*@YL!TJ'-XXJCAR'9L<)QPTG-* M<#KF],+9Q)GOW.8\YV+CLM[EO"OBZN%:Z-KO)N,6XE;I]MA=W3W.O=E]QL/" M8YW'>4^TI[?G;L]A+V4OEE>CU\P*JQ7K5_1XD[R#O"N]G_CH^_!]NGQAWQ6^ M>WP?KM1:R5O9X0?\O/SV^#WRU_%/\_\^`!/@'U`5\#30-#`WL#>($A05U!3T M)M@YN"3X08ANB#"D.U0R-#*T,70NS#6L-&QDE?&J]:NNARN$<\,[([`1H1$- M$;.KW5;O73T>:1%9$#FT1F=-UIJK:Q76)JT]$R49Q8PZ&8V.#HMNBO[`]&/6 M,6=CO&*J8V98+JQ]K.=L1W89>XICQRGE3,3:Q9;&3L;9Q>V)FXIWB"^/G^:Z M<"NY+Q,\$VH2YA+]$H\D+B2%);4FXY*CDT_Q9'B)O)X4E92LE(%4@]2"U)$T MF[2]:3-\;WY#.I2^)KU30!7]3/4)=85;A:,9]AE5&6\S0S-/9DEG\;+ZLO6S M=V1/Y+CG?+T.M8ZUKCM7+7=S[NAZI_6U&Z`-,1NZ-VILS-\XOLECT]'-A,V) MFW_(,\DKS7N])6Q+5[YR_J;\L:T>6YL+)`KX!WSWM9?2RPK+7>Z/V7BU?5EZSC[!/N&^DPJ>B<[_F_EW[/U3&5]ZI5'\8-#0H-10T?C_".C!P-/-K3:-78V*345-(,-PN;IXY%'KOYC>LWG2V&+;6M MM-:BX^"X\/BS;Z._'3KA?:+[).-DRW=:WU6W4=H*VZ'V[/:9COB.D<[PSH%3 M*TYU=]EVM7UO]/V1TVJGJ\[(GBDY2SB;?W;A7,ZYV?.IYZ\+UVY['[Y8J]3[[DK=E=.7[6Y>NH:XUK'=N;70/+!\X..@Q>N.5ZZ_)MK]O7[ZR\,S`4,G1W.')XY"[[ M[N2]I'LO[V?$CJ4?ECY4>U_VH]V/KB.7(F5'7T;XG04\>C+'& MGO^4_M.'\?RGY*?E$ZH3C9-FDZ>GW*=N/EO];/QYZO/YZ8*?I7^N?J'[XKM? M''_IFUDU,_Z2_W+AU^)7\J^.O%[VNGO6?_;QF^0W\W.%;^7?'GW'>-?[/NS] MQ'SF!^R'BH]Z'[L^>7]ZN)"\L/";``,`]X3S^PH-"F5N9'-T%LM-38X("TS,#<@,C`P,"`Q,#`W72]!7!E+T9O;G1$97-C%LM-34X M("TS,#<@,C`P,"`Q,#(V72]!7!E+T9O M;G1$97-C'1'4W1A=&4O4T$@ M9F%L7!E+UA-3"],96YG=&@@,S4Y-R]4>7!E+TUE=&%D871A M/CYS=')E86T-"CP_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H M:4AZDY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#0N,"UC,S$V(#0T M+C(U,SDR,2P@4W5N($]C="`P,2`R,#`V(#$W.C$T.C,Y(CX*("`@/')D9CI2 M1$8@>&UL;G,Z&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D M8R]E;&5M96YT&UL.FQA;F<] M(G@M9&5F875L="(^36EC&UL;G,Z>&%P M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(CX*("`@("`@("`@/'AA M<#I#&%P.D-R96%T;W)4;V]L/E!38W)I<'0U M+F1L;"!697)S:6]N(#4N,BXR/"]X87`Z0W)E871O&%P34TZ26YS=&%N8V5)1#YU=6ED.F8T,3,Q8CAB M+6(W83@M-#0W-RUB,&9B+3EF-S8P,64T-S1C9#PO>&%P34TZ26YS=&%N8V5) M1#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@(#PO')E9@T*,"`V#0HP,#`P M,#`P,#`P(#8U-3,U(&8-"C`P,#`P,#8U-#@@,#`P,#`@;@T*,#`P,#`P-C4X M,B`P,#`P,"!N#0HP,#`P,#`V-C`V(#`P,#`P(&X-"C`P,#`P,#8V-3<@,#`P M,#`@;@T*,#`P,#`Q,#,S,2`P,#`P,"!N#0IT -----END PRIVACY-ENHANCED MESSAGE-----